New combo therapy aims to control stubborn leukemia
NCT ID NCT04169737
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 30 times
Summary
This study tests whether adding an immunotherapy drug (obinutuzumab) early to a two-drug combo (acalabrutinib and venetoclax) can better control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that is high-risk, has returned, or stopped responding to treatment. About 168 adults will receive the two-drug backbone, with half also getting the third drug early. The goal is to see if the triple therapy can clear cancer cells from the bone marrow more effectively. This is not a cure, as ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.